Business Context and Reporting Period
This Form 8-K Current Report was filed by Artelo Biosciences, Inc. on October 26, 2025. The filing discloses significant changes to the company's executive leadership and executive compensation arrangements, specifically the appointment of a new Chief Financial Officer and an amendment to the existing CEO's employment agreement.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on personnel appointments and contractual terms.
Material Changes
Appointment of Chief Financial Officer
- New Officer: Mark Spring was appointed as Chief Financial Officer, Treasurer, principal financial officer, and principal accounting officer, effective November 1, 2025.
- Predecessor: Mr. Spring replaces Gregory Gorgas in the roles of Treasurer, principal financial officer, and principal accounting officer.
- Background: Mr. Spring previously served as CFO for Hyperion Therapeutics, Prometheus Laboratories, Veracyte, Sotera Wireless, and Genoptix, and as interim CFO for LENZ Therapeutics.
Compensation Arrangements
- Mr. Spring's Compensation:
- Base Salary: $250,000 annually.
- Target Bonus: 35% of base salary.
- Severance (Involuntary Termination): 12 months of base salary (18 months if connected to a change in control).
- Equity: Subject to Board discretion; full acceleration upon change in control.
- Mr. Gorgas's Agreement Amendment:
- Severance increased from 12 months to 24 months of base salary and target bonus (36 months if connected to a change in control).
- COBRA reimbursement increased from 12 months to 24 months (36 months if connected to a change in control).
- Equity vesting acceleration upon involuntary termination outside a change in control was removed; replaced with partial acceleration for awards vesting within 24 months post-termination.
- Severance benefits are now subject to the company's clawback policy.
Guidance, Outlook, and Risks
The filing contains no financial guidance, operational outlook, or discussion of market risks. The primary contingency noted is the execution of customary release of claims required for severance benefits to be paid upon involuntary termination.
Investor Verification Checklist
- Verify the effective date of Mark Spring's appointment (November 1, 2025) and the transition of duties from Gregory Gorgas.
- Review the full text of the Spring Employment Agreement (Exhibit 10.1) for specific performance objectives tied to the 35% bonus.
- Review the Employment Agreement Amendment (Exhibit 10.2) to understand the specific definitions of "Good Reason" and "Cause" that trigger the increased severance for Mr. Gorgas.
- Confirm the impact of the new clawback policy on Mr. Gorgas's potential severance payout.